Christopher Granger, MD: Antithrombotic Therapy in Patients with Atrial Fibrillation

July 6, 2021
Connor Iapoce

Connor Iapoce is an associate editor for HCPLive and joined the MJH Life Sciences team in April 2021. He graduated from The College of New Jersey with a degree in Journalism and Professional Writing. He enjoys listening to records, going to concerts, and playing with his cat Squish. You can reach him at

Growing evidence shows promise of stroke prevention with anti-thrombotic therapy in patients with AF.

In an interview with HCPLive®, Christopher Granger, MD, Duke University School of Medicine, spoke on the growing evidence around the use of anti-thrombotic therapy across cardiovascular disease.

Granger recently took part in an HCPLive® State of the Science "Institutional Perspectives in Cardiology: Cardiovascular Risk Management" event, chaired by Manesh Patel, MD, Duke University School of Medicine.

He presented a talk titled "Atrial Fibrillation: What Have We Learned About NOACs in Special Populations?"

"We've learned so much over the past 10 years about improving Stroke Prevention through anti thrombotic therapy for atrial fibrillation," Granger said. "And I think there are some really important recent observations that can help clinicians better apply the evidence better treat their patients with atrial fibrillation, with anti thrombotic therapy."

He noted his talk included a discussion on the undertreatment of AF, safety barriers and the need for further research on mechanical valves in treatment, patients with renal impairment, and patients with coronary stents and AF.